In one of the previous PET studies [3], high TSPO binding was reported in the areas beyond the MRI-defined MS lesions.
As Gd and/or T2/FLAIR high-intensity lesions were considered to reflect on inflammatory demyelization, and the increase of TSPO binding was reported in such areas in previous PET studies [2, 8], the feasibility of a quantitative evaluation of MRI-defined MS lesions was explored.
Notably, in line with our observations, no significant change in binding was reported in the anterior cingulate cortex [ 21].
In addition, lower D2/D3 binding was reported in a positron emission tomography study in PD with comorbid PG compared with a control group with PD only [ 44].
A large number of QSAR models for ER binding are reported in the literature (Bradbury et al. 1996; Sadler et al. 1998; Waller et al. 1996; Wiese et al. 1997; Zheng and Tropsha 2000), including our own (Tong et al. 1997a, 1997b, 1998; Xing et al. 1999).
In preweanling animals, across all compounds and treatment protocols, QNB binding was reported to increase in six studies, decrease in two studies, and not change in four studies (Table 5).
A deletion of 2 bp in box B in vivo, which abolishes TFIIIC binding, was reported to result in rearrangement or destabilization of the nucleosomes in the gene-flanking regions [ 39], suggesting these nucleosomes in vivo are organized by TFIIIC-dependent chromatin remodeling.
The low 11 C radioactivity in the white matter, where GlyT1 binding was reported to be high in in vitro ARG studies, was consistent with our previous ex vivo studies of 125I]IMPB [24] and previous PET studies with other GlyT1 ligands [19 21].
The amino acid sequence of the Bub3-binding domain of Bub1 is reported in Figure 2D.
We chose these PCB congeners because they have known estrogenic activity and their binding affinity to the ER is reported in the literature (Table 1).
